

WHAT IS CLAIMED IS:

1. A compound of formula:



, or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, which is:



.

3. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, or claim 2, in the manufacture of a medicament.

4. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, or claim 2, in the manufacture of a medicament for reducing serum uric acid levels in a human.

5. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, or claim 2, in the manufacture of a medicament for treating hyperuricemia in a human.

6. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, or claim 2, in the manufacture of a medicament for treating hyperuricemia in a human with gout.

7. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, or claim 2, in the manufacture of a medicament for treating gout in a human.

~~8. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, or claim 2, in the manufacture of a medicament for treating or preventing a condition characterized by abnormal tissue or organ levels of uric acid in an individual.~~

~~9.~~8. The use according to claim ~~8~~3, wherein the condition is gout, a recurrent gout attack, gouty arthritis, hyperuricaemia, hypertension, a cardiovascular disease, coronary heart disease, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis, sarcoidosis, hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency or a combination thereof.

~~10. The use according to any one of claims 3-9, in combination with a xanthine oxidase inhibitor.~~

~~11. The use according to claim 10, wherein the xanthine oxidase inhibitor is allopurinol.~~

~~12. The use according to claim 10, wherein the xanthine oxidase inhibitor is febuxostat.~~

~~13.~~9. A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, or claim 2, and a pharmaceutically acceptable carrier.

~~14.~~10. A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, or claim 2, together with a xanthine oxidase inhibitor and a pharmaceutically acceptable carrier.

~~15.~~11. The pharmaceutical composition according to claim ~~14~~10, wherein the xanthine oxidase inhibitor is allopurinol.

~~16.~~12. The pharmaceutical composition according to claim ~~14~~10, wherein the xanthine oxidase inhibitor is febuxostat.